DK0756708T3 - Anvendelse af humant neutrophil-lipocalin (HNL) som en diagnostisk markør og anti-HNL-antistof-præparat - Google Patents

Anvendelse af humant neutrophil-lipocalin (HNL) som en diagnostisk markør og anti-HNL-antistof-præparat

Info

Publication number
DK0756708T3
DK0756708T3 DK95917540T DK95917540T DK0756708T3 DK 0756708 T3 DK0756708 T3 DK 0756708T3 DK 95917540 T DK95917540 T DK 95917540T DK 95917540 T DK95917540 T DK 95917540T DK 0756708 T3 DK0756708 T3 DK 0756708T3
Authority
DK
Denmark
Prior art keywords
hnl
pct
human neutrophil
antibody preparation
diagnostic marker
Prior art date
Application number
DK95917540T
Other languages
English (en)
Inventor
Per Venge
Original Assignee
Pharmacia Diagnostics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20393731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0756708(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Diagnostics Ab filed Critical Pharmacia Diagnostics Ab
Application granted granted Critical
Publication of DK0756708T3 publication Critical patent/DK0756708T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK95917540T 1994-04-21 1995-04-21 Anvendelse af humant neutrophil-lipocalin (HNL) som en diagnostisk markør og anti-HNL-antistof-præparat DK0756708T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9401351A SE9401351D0 (sv) 1994-04-21 1994-04-21 A method for diagnosis
PCT/SE1995/000439 WO1995029404A1 (en) 1994-04-21 1995-04-21 Use of human neutrophil lipocalin (hnl) as a diagnostic marker and anti-hnl-antibody preparation

Publications (1)

Publication Number Publication Date
DK0756708T3 true DK0756708T3 (da) 2001-10-29

Family

ID=20393731

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95917540T DK0756708T3 (da) 1994-04-21 1995-04-21 Anvendelse af humant neutrophil-lipocalin (HNL) som en diagnostisk markør og anti-HNL-antistof-præparat

Country Status (10)

Country Link
US (1) US6136526A (da)
EP (1) EP0756708B1 (da)
JP (1) JP3544544B2 (da)
AT (1) ATE202849T1 (da)
AU (1) AU2355195A (da)
DE (1) DE69521608T2 (da)
DK (1) DK0756708T3 (da)
ES (1) ES2160709T3 (da)
SE (1) SE9401351D0 (da)
WO (1) WO1995029404A1 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2356867A1 (en) * 1998-12-28 2000-07-06 Kabushiki Kaisya Advance System for identifying microorganism
FI115165B (fi) 2001-06-04 2005-03-15 Aboatech Ab Oy Menetelmä infektion laadun määrittämiseksi
US20030119209A1 (en) * 2001-12-21 2003-06-26 Kaylor Rosann Marie Diagnostic methods and devices
US7056702B2 (en) * 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
DK2360475T3 (da) * 2003-03-27 2020-01-06 Childrens Hospital Med Ct Fremgangsmåde og kit til detektion af tidlig indtræden af renal tubulær celleskade
US20050048617A1 (en) 2003-08-18 2005-03-03 Medimmune, Inc. Humanization of antibodies
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
NZ555926A (en) 2004-12-20 2008-11-28 Antibodyshop As Determination of neutrophil gelatinase-associated lipocalin (NGAL) as a diagnostic marker for renal disorders
EP1869192B1 (en) 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
EP2035835B1 (en) 2006-05-30 2011-12-28 Antibodyshop A/S Methods for rapid assessment of severity of a trauma
EP2602624A1 (en) 2006-08-07 2013-06-12 Antibodyshop A/S Diagnostic test to exclude significant renal injury
CN101680903A (zh) 2007-03-21 2010-03-24 比奥波托诊断股份公司 肾损伤的诊断试验
US8846036B2 (en) * 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090123946A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090124022A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
WO2009062520A1 (en) * 2007-11-15 2009-05-22 Bioporto Diagnostics A/S Diagnostic use of individual molecular forms of a biomarker
EP2257813A4 (en) * 2008-03-12 2011-11-02 Univ Columbia NGAL WITH HIGH MOLECULAR WEIGHT AS BIOMARKER FOR CHRONIC KIDNEY DISEASE
US7977110B2 (en) * 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions
US20100105150A1 (en) * 2008-10-24 2010-04-29 Abbott Laboratories Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal
CA2744434C (en) 2008-11-21 2017-10-03 Phadia Ab Methods, devices and kits for detecting or monitoring acute kidney injury
US20100233739A1 (en) * 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to diagnose unilateral and bilateral urinary obstruction
US9709565B2 (en) 2010-04-21 2017-07-18 Memed Diagnostics Ltd. Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof
WO2011149962A1 (en) 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
NL2007112C2 (en) 2011-07-14 2013-01-15 Brainlabs B V Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness.
CA2863819C (en) 2012-02-09 2021-11-23 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
EP2925337B1 (en) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof
US10303846B2 (en) 2014-08-14 2019-05-28 Memed Diagnostics Ltd. Computational analysis of biological data using manifold and a hyperplane
US20170234873A1 (en) 2014-10-14 2017-08-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
WO2016079219A1 (en) * 2014-11-19 2016-05-26 Koninklijke Philips N.V. Diagnostic method employing hnl
US20170269081A1 (en) 2014-12-11 2017-09-21 Memed Diagnostics Ltd. Marker combinations for diagnosing infections and methods of use thereof
WO2017149548A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Rna determinants for distinguishing between bacterial and viral infections
CN108699609A (zh) 2016-03-03 2018-10-23 米密德诊断学有限公司 分析rna用于诊断感染类型
WO2018001932A1 (en) 2016-06-30 2018-01-04 Koninklijke Philips N.V. Device, system and method for detecting an analyte in a body fluid sample containing a plurality of cells
US11340223B2 (en) 2016-07-10 2022-05-24 Memed Diagnostics Ltd. Early diagnosis of infections
CA3027341A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
US11353456B2 (en) 2016-09-29 2022-06-07 Memed Diagnostics Ltd. Methods of risk assessment and disease classification for appendicitis
EP3519833B1 (en) 2016-09-29 2024-08-14 MeMed Diagnostics Ltd. Methods of prognosis and treatment
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
WO2024246048A1 (en) 2023-06-01 2024-12-05 P & M Venge Ab Specific detection of homodimeric hnl
CN119375492B (zh) * 2024-12-27 2025-05-30 北京水木翼锋诊断技术有限公司 Hnl在制备用于鉴定血流感染的试剂中的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US5200319A (en) * 1989-10-27 1993-04-06 The General Hospital Corporation Diagnosis of glomerulonephritis

Also Published As

Publication number Publication date
DE69521608T2 (de) 2002-05-08
AU2355195A (en) 1995-11-16
ATE202849T1 (de) 2001-07-15
JP3544544B2 (ja) 2004-07-21
SE9401351D0 (sv) 1994-04-21
US6136526A (en) 2000-10-24
EP0756708A1 (en) 1997-02-05
EP0756708B1 (en) 2001-07-04
ES2160709T3 (es) 2001-11-16
WO1995029404A1 (en) 1995-11-02
DE69521608D1 (de) 2001-08-09
JPH09512630A (ja) 1997-12-16

Similar Documents

Publication Publication Date Title
ES2160709T3 (es) Uso de lipocalina de neutrofilos humanos (hnl) como un marcador de diagnostico y preparacion de anticuerpo anti-hnl.
Zahavi et al. Enhanced in vivo platelet “release reaction” in old healthy individuals
Johnson et al. Detection of high‐risk groups and individuals for periodontal diseases: Evidence for the existence of high‐risk groups and individuals and approaches to their detection
Beck et al. Oral disease, cardiovascular disease and systemic inflammation.
English et al. Reproducibility of reported measurements of sun exposure in a case-control study.
Geivelis et al. Measurements of interleukin‐6 in gingival crevicular fluid from adults with destructive periodontal disease
Abikoff et al. Logical memory subtest of the Wechsler Memory Scale: age and education norms and alternate-form reliability of two scoring systems
Pederson et al. Salivary levels of α2-macroglobulin, α1-antitrypsin, C-reactive protein, cathepsin G and elastase in humans with or without destructive periodontal disease
Plagnat et al. Elastase, α2‐macroglobulin and alkaline phosphatase in crevicular fluid from implants with and without periimplantitis
Johnston Relationships between body composition and anthropometry
Kopač et al. Viability of fibroblasts in cell culture after treatment with different chemical retraction agents
FI854488A0 (fi) Kontrastmedel.
George et al. Detection of root resorption using dentin and bone markers
Bianchi et al. Overhead electricity power lines and childhood leukemia: a registry-based, case-control study
Kahaleh et al. Assessment of vascular involvement
Kavanagh et al. Variation of salivary calcium, phosphate and buffering capacity in adolescents
AU635050B2 (en) Method for diagnosis of periodontal disease by detection of alanine aminotransferase
Piché et al. The glycosylated hemoglobin assay for diabetes: its value to the periodontist: two case reports
Streckfus et al. Aging and salivary cytokine concentrations as predictors of whole saliva flow rates among women: a preliminary study
Lachmann et al. Reliability of findings around healthy implants in association with oral hygiene measures: A clinical, microbiological, and immunological follow‐up in edentulous patients
Guo et al. Associations of salivary BPIFA1 protein in chronic periodontitis patients with type 2 diabetes mellitus
Trull et al. Psychometric properties and factor structure of the Fear Questionnaire phobia subscale items in two normative samples
Grossman et al. Some observations on the pH of saliva
Briffa et al. Chronologic and dental ages of Maltese schoolchildren: a pilot study
Leske et al. Three‐year root caries increments: implications for clinical trials